Nebenwirkungen · Zeposia
Zeposia 0.23 mg hard capsules Zeposia 0.46 mg hard capsules Zeposia 0.92 mg hard capsules · Abschnitt 4.8 · PDF-Seite 12
HOS-142279 · Präparat HOS-098792
Increased blood pressure In MS clinical studies, patients treated with ozanimod had an average increase of approximately 1-2 mm Hg in systolic pressure over IFN β-1a IM, and approximately 1 mm Hg in diastolic pressure over IFN β-1a IM. The increase in systolic pressure was first detected after approximately 3 months of treatment initiation and remained stable throughout treatment. Hypertension-related events (hypertension, essential hypertension, and blood pressure increased) were reported as an adverse reaction in 4.5% of patients treated with ozanimod 0.92 mg and in 2.3% of patients treated with IFN β-1a IM.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-03T10:34:00Z · SHA-256 e1efa1853d4dbc887f7da13387736c7007c19f29d49a626a00d40b88c00a6a21 · Passage 2efc3f3ffd7e47334f52722cd5d8b52be1120821d6be1a3deac12d2d91241065 · Zeichen 7462–8079 im Abschnitt